Natural fragment · 8 amino acids · 824.9 Da

Davunetide studies and research data

PepBank has 90 davunetide studies with results. 78 of them gave davunetide, with 297 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 297 results and 178 papers. Newer studies from Europe PMC

Results in people

12% of 297 results

Results in animals

138

46% of 297 results

Results in lab cells

122

41% of 297 results

From computer models

0% of 297 results

The molecule

Davunetide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Davunetide is the ADNP fragment NAPVSIPQ, also called NAP or AL-108. Its research concerns microtubule-associated processes. A phase 2/3 trial did not establish benefit in progressive supranuclear palsy.

Kind: Natural fragment · 8 residues
Identifiers: ChEMBLCHEMBL2103826 (opens in a new tab)PubChem CID9832404 (opens in a new tab)UNIIGF00K3IIWE (opens in a new tab)DrugBankDB12613 (opens in a new tab)CAS211439-12-2KEGGD09401 (opens in a new tab)
Parent: Fragment of Activity-dependent neuroprotector homeobox protein · residues 354-361UniProt Q9H2P0 residues 354-361 match NAPVSIPQ.
Development: Phase 3Allon Therapeutics (historical clinical program). Exonavis Therapeutics Ltd. (current FDA orphan-designation sponsor).The completed PSP study reached phase 2/3 and did not establish benefit. Five distinct completed interventional registrations report actual enrollment. None is a withdrawn zero-enrollment registration. FDA lists Exonavis as the current ADNP orphan-designation sponsor. These records do not establish current recruitment or a registered ADNP syndrome trial. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Microtubule end-binding protein 1 (EB1)MAPRE1	Microtubule end binding protein interaction through the sip motif	Preclinical experiments linked NAP activity to EB1 and EB3. Silencing either protein inhibited NAP-mediated cell protection. This does not establish clinical target engagement.Source (opens in a new tab)
Microtubule end-binding protein 3 (EB3)MAPRE3	Microtubule end binding protein interaction through the sip motif	Preclinical experiments linked NAP activity to EB1 and EB3. Silencing either protein inhibited NAP-mediated cell protection. This does not establish clinical target engagement.Source (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

8 amino acids

H-

NAPVSIPQ

Parent: Activity-dependent neuroprotector homeobox protein

No sequence is listed for the parent, so no alignment is shown.UniProt Q9H2P0 residues 354-361 match NAPVSIPQ.

Properties

From identity sources

Formula: C₃₆H₆₀N₁₀O₁₂
Molecular weight: 824.9 g/mol
Monoisotopic mass: 824.4392 Da

PubChem CID 9832404(opens in a new tab)retrieved 2026-10-27
ChEMBL CHEMBL2103826(opens in a new tab)retrieved 2026-10-27
GSRS UNII GF00K3IIWE(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 824.93 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 824.4392 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 6.10; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: −0.06; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.062; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Instability index: 77.38; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 97.5; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 0.60 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): Not calculated; The sequence is too short for this method.
pI with each pKa set: EMBOSS 6.10Bjellqvist (ExPASy) 5.53IPC peptide 5.97IPC protein 5.98

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 6.10 · Net charge at pH 7.4: −0.06

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	1.00
1	1.00
2	0.98
3	0.80
4	0.28
5	0.04
6	0.00
7	−0.02
8	−0.20
9	−0.72
10	−0.96
11	−1.00
12	−1.00
13	−1.00
14	−1.00

Composition

Hydrophobic38% (3)A I V
Polar38% (3)N Q S
Special25% (2)P

8 residues. Each residue counts in one class; F and W count as aromatic.

A Ala1 · 13%

I Ile1 · 13%

L Leu0 · 0%

M Met0 · 0%

V Val1 · 13%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys0 · 0%

R Arg0 · 0%

D Asp0 · 0%

E Glu0 · 0%

N Asn1 · 13%

Q Gln1 · 13%

S Ser1 · 13%

T Thr0 · 0%

C Cys0 · 0%

G Gly0 · 0%

P Pro2 · 25%

3D structure

PredictedAlphaFold DB · Q9H2P0

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 9832404(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)N

Results by area

Davunetide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

90 of 178 studies have results (51%), published 1999 to 2026. Top row: every study. Bottom row: studies with results about Davunetide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies178 in all, 1985 to 2026

Studies with results90 in all, 1999 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Davunetide studies on memory and thinking

37 results · people 14 · animals 23 · lab 0

Top 3 of 37 results

In people with amnestic mild cognitive impairment, AL-108 and placebo did not significantly differ on the combined memory score.Dementia and geriatric cognitive disorders, 2013
In people with schizophrenia, davunetide did not significantly change cognition scores compared with placebo.Schizophrenia research, 2012
In women with memory impairment, high-dose davunetide improved digit span more than matched placebo.Translational psychiatry, 2024

Davunetide studies on brain and nerves

120 results · people 6 · animals 66 · lab 48

Top 5 of 120 results

In people with schizophrenia, high-dose davunetide showed a trend toward higher NAA/Cr than placebo.Neuropsychopharmacology, 2013
In diabetic rats, NAP reduced retinal cell death compared with vehicle.Journal of molecular neuroscience, 2014
In worms with a CAMSAP disorder model, davunetide had variable effects on convulsions.Epilepsy research, 2026
In women with PSP, protection of ventricular volume with davunetide corresponded to clinical benefit.Translational psychiatry, 2023
In diabetic rats, NAP improved retinal cell survival compared with vehicle.Journal of molecular neuroscience, 2014

Davunetide studies on daily life and fitness

15 results · people 6 · animals 9 · lab 0

Top 5 of 15 results

In patients with PSP, davunetide did not change PSPRS scores more than placebo.The Lancet. Neurology, 2014
In mice, motor function did not differ significantly between NAP-treated and comparison groups.Neuroscience letters, 2004
In women with PSP, davunetide slowed loss of daily function by 39 weeks.Translational psychiatry, 2023
In ovariectomized mice, daily nasal NAP apparently increased weight-adjusted grip strength compared with the sham-treated OVX group.Frontiers in neuroscience, 2026
In people with progressive supranuclear palsy, a clinical analysis found a significant davunetide treatment effect favoring women.Molecular psychiatry, 2026

Davunetide studies on side effects

7 results · people 6 · animals 1 · lab 0

Top 5 of 7 results

In patients with PSP, davunetide and placebo each had 54 serious adverse events.The Lancet. Neurology, 2014
In patients with PSP, nosebleeds occurred more often with davunetide than placebo.The Lancet. Neurology, 2014
In people with amnestic mild cognitive impairment, AL-108 was generally safe and well tolerated.Dementia and geriatric cognitive disorders, 2013
In patients with PSP, a runny nose occurred more often with davunetide than placebo.The Lancet. Neurology, 2014
In people with schizophrenia, the davunetide trial reported no significant side effects or adverse events.Schizophrenia research, 2012

Davunetide studies on mood, stress and behavior

6 results · people 2 · animals 4 · lab 0

Top 4 of 6 results

In women with PSP, the depression scale showed protection with davunetide at 52 weeks.Translational psychiatry, 2023
In people with schizophrenia, davunetide did not significantly change symptom ratings compared with placebo.Schizophrenia research, 2012
In mice, daily intranasal NAP reduced anxiety measured by time in open maze arms after 5 months.Neuroscience letters, 2004
In mice with mutated DISC1, NAP reduced anxiety, whereas Risperidone did not.Scientific reports, 2015

Davunetide studies on blood levels and clearance

6 results · people 2 · animals 1 · lab 3

Top 4 of 6 results

In men undergoing heart bypass surgery, intravenous davunetide potentially accumulated with dose over time.Translational psychiatry, 2025
In lab tests, NAP entered astrocytes before binding tubulin and promoting microtubule assembly.Journal of Alzheimer's disease, 2004
In women undergoing heart bypass surgery, intravenous davunetide concentrations declined or did not change over time.Translational psychiatry, 2025
In mice, 39% of fetal radioactivity traveled with intact labeled NAP 60 min after administration.The Journal of pharmacology and experimental therapeutics, 2001

Davunetide studies on survival and serious illness

3 results · people 1 · animals 2 · lab 0

3 results

In patients with PSP, 11 died with davunetide versus ten with placebo.The Lancet. Neurology, 2014
In mice, NAP alone reduced fetal death compared with alcohol alone.The Journal of pharmacology and experimental therapeutics, 2001
In mice with an ALS model, NAP treatment increased life span.Neurobiology of disease, 2013

Davunetide studies on receptors and cell signals

89 results · people 0 · animals 31 · lab 58

Top 5 of 89 results

In Map6-deficient mice, NAP reversed reduced hippocampal Becn1 mRNA, whereas clozapine did not.Autophagy, 2014
In diabetic rats, NAP restored retinal cleaved caspase-3 levels compared with vehicle.Journal of molecular neuroscience, 2014
In mice, NAP corrected sex-specific differences in spleen gene activity.Biological psychiatry, 2022
In cells from mice grown in high glucose, NAP reduced cell viability.Journal of molecular neuroscience, 2014
In cells, NAP did not affect dividing cells.Current Alzheimer research, 2007

Davunetide studies on immune system and inflammation

8 results · people 0 · animals 1 · lab 7

Top 5 of 8 results

In mice with head injury, NAP treatment decreased injury-associated Mac-1 expression at the injury site.Current Alzheimer research, 2005
In cells, NAP reduced CD69 expression in human immune cells.Neuroimmunomodulation, 2010
In cells, NAP reduced the inflammatory cytokine TNF-alpha.Annals of the New York Academy of Sciences, 2006
In cells, NAP reduced CD154 expression in human immune cells.Neuroimmunomodulation, 2010
In cells, NAP reduced the inflammatory cytokine IL-16.Annals of the New York Academy of Sciences, 2006

Davunetide studies on cells, genes and aging

4 results · people 0 · animals 0 · lab 4

Top 3 of 4 results

In lab tests with Parkinson's disease cells, NAP reduced trapping of alpha-synuclein oligomers by mitochondria.Biochimica et biophysica acta, 2014
In cells expressing A53T alpha-synuclein, NAP completely reversed adverse effects on mitochondrial dynamics.Experimental brain research, 2017
In lab tests with Parkinson's disease cells, NAP decreased mitochondrial ubiquitination.Biochimica et biophysica acta, 2014

Davunetide studies on growth hormone and growth

2 results · people 0 · animals 0 · lab 2

2 results

In lab tests, NAP prevented the reduction in mouse embryo somite number compared with ethanol alone.Proceedings of the National Academy of Sciences of the United States of America, 2003
In lab tests, l-NAP reduced ethanol-induced growth retardation in mouse embryos.The Journal of pharmacology and experimental therapeutics, 2004

Trials and papers

Davunetide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

5 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (5 of 5)

5 trials · 5 completed · 1 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2006200820102012

Ph 2
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
NCT00404014
Aug 2006 to Jun 2008
Ph 2
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
NCT00422981
Jan 2007 to Jan 2008
Ph 2
AL-108
NCT00505765
Jul 2007 to Apr 2009
Ph 1
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
NCT01056965
Jan 2010 to Dec 2012
Ph 2/3
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
NCT01110720
Oct 2010 to Dec 2012

5 trials · 5 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT01110720

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Allon Therapeuticsn = 313Oct 2010 to Dec 2012

Progressive Supranuclear Palsy

Trial page ClinicalTrials.govUpdated 17 Jan 2013

CompletedPhase 2Results postedNCT00505765

A Multicenter Study of NAP (AL-108) in Schizophrenia

University of California, Los Angelesn = 63Jul 2007 to Apr 2009

Schizophrenia

Trial page ClinicalTrials.govUpdated 10 Mar 2017

CompletedPhase 2NCT00404014

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Allon Therapeuticsn = 234Aug 2006 to Jun 2008

Mild Cognitive Impairment

Trial page ClinicalTrials.govUpdated 24 Oct 2012

CompletedPhase 2NCT00422981

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Allon Therapeuticsn = 144Jan 2007 to Jan 2008

Mild Cognitive Impairment, So Stated

Trial page ClinicalTrials.govUpdated 24 Oct 2012

CompletedPhase 1NCT01056965

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

University of California, San Franciscon = 12Jan 2010 to Dec 2012

Predicted Tauopathies, Including · Progressive Supranuclear Palsy · Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17 · Corticobasal Degeneration Syndrome · Progressive Nonfluent Aphasia

Trial page ClinicalTrials.govUpdated 5 Apr 2019

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

178 studies match. Retracted studies are left out.

Showing 25 of 178 studiesquery qry_9cbe044d628da76d1cd7b653

Studies with results

90 studies in all, 18 on this page

Animal study (in vivo) · mouse · 1999

7 results

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.

Bassan et al. 1999Journal of neurochemistrycited by 320

PMID 10037502DOI 10.1046/j.1471-4159.1999.0721283.xPUB-10037502

Rights unknown7 results where Davunetide was given

Source link See results (7)

Randomized controlled trial · 2014

7 results

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Boxer et al. 2014The Lancet. Neurologyn = 313cited by 237

PMID 24873720PMC4129545DOI 10.1016/s1474-4422(14)70088-2PUB-24873720

Rights unknown7 results where Davunetide was given

Source link See results (7)

Animal study (in vivo) · mouse · 2007

2 results

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman et al. 2007The Journal of pharmacology and experimental therapeuticscited by 182

PMID 17720885DOI 10.1124/jpet.107.129551PUB-17720885

Full text at the publisher2 results where Davunetide was given

Publisher page See results (2)

Animal study (in vivo) · mouse · 2008

4 results

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Matsuoka et al. 2008The Journal of pharmacology and experimental therapeuticscited by 169

PMID 18199809DOI 10.1124/jpet.107.130526PUB-18199809

Full text at the publisher4 results where Davunetide was given

Publisher page See results (4)

Animal study (in vivo) · mouse · 2013

2 results

Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.

Liu et al. 2013Biomaterialscited by 136

PMID 23453061DOI 10.1016/j.biomaterials.2013.02.003PUB-23453061

Full text at the publisher2 results where Davunetide was given

Publisher page See results (2)

Animal study (in vivo) · mouse · 2001

5 results

Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.

Spong et al. 2001The Journal of pharmacology and experimental therapeuticscited by 113

PMID 11303069DOI 10.1016/s0022-3565(24)29596-3PUB-11303069

Full text at the publisher2 results where Davunetide was given (plus 3 on tools or combinations, listed separately)

Publisher page See results (5)

Animal study (in vivo) · mouse · 2013

3 results

B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide.

Liu et al. 2013Bioconjugate chemistrycited by 107

PMID 23718945DOI 10.1021/bc400055hPUB-23718945

Full text at the publisher3 results where Davunetide was given

Publisher page See results (3)

Randomized controlled trial · 2012

9 results

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Javitt et al. 2012Schizophrenia researchn = 63cited by 100

PMID 22169248DOI 10.1016/j.schres.2011.11.001PUB-22169248

Full text at the publisher9 results where Davunetide was given

Publisher page See results (9)

Animal study (in vivo) · mouse · 2009

3 results

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

Shiryaev et al. 2009Neurobiology of diseasecited by 93

PMID 19264130DOI 10.1016/j.nbd.2009.02.011PUB-19264130

Full text at the publisher3 results where Davunetide was given

Publisher page See results (3)

Randomized controlled trial · 2013

3 results

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.

Morimoto et al. 2013Dementia and geriatric cognitive disordersn = 144cited by 93

PMID 23594991DOI 10.1159/000348347PUB-23594991

Full text at the publisher3 results where Davunetide was given

Publisher page See results (3)

Animal study (in vivo) · mouse · 2013

9 results

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

Jouroukhin et al. 2013Neurobiology of diseasecited by 93

PMID 23631872DOI 10.1016/j.nbd.2013.04.012PUB-23631872

Full text at the publisher9 results where Davunetide was given

Publisher page See results (9)

Animal study (in vivo) · mouse · 2018

8 results

Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.

Hacohen-Kleiman et al. 2018The Journal of clinical investigationcited by 93

PMID 30106381PMC6205398DOI 10.1172/jci98199PUB-30106381

Rights unknown8 results where Davunetide was given

Source link See results (8)

In vitro (cells) · 2014

8 results

The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.

Esteves et al. 2014Biochimica et biophysica actacited by 92

PMID 24120997DOI 10.1016/j.bbadis.2013.10.003PUB-24120997

Full text at the publisher8 results where Davunetide was given

Publisher page See results (8)

In vitro (cells) · 2017

13 results

ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

Ivashko-Pachima et al. 2017Molecular psychiatrycited by 82

PMID 28115743DOI 10.1038/mp.2016.255PUB-28115743

Full text at the publisher13 results where Davunetide was given

Publisher page See results (13)

Animal study (in vivo) · mouse · 2014

5 results

New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Merenlender-Wagner et al. 2014Autophagycited by 73

PMID 25484074PMC4502702DOI 10.4161/15548627.2014.984274PUB-25484074

Rights unknown4 results where Davunetide was given (plus 1 on tools or combinations, listed separately)

Source link See results (5)

Ex vivo tissue · mouse · 2003

2 results

Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.

Wilkemeyer et al. 2003Proceedings of the National Academy of Sciences of the United States of Americacited by 70

PMID 12808140PMC166265DOI 10.1073/pnas.1331636100PUB-12808140

Rights unknown2 results where Davunetide was given

Source link See results (2)

In vitro (cells) · rat · 2005

3 results

PolyADP-ribosylation is involved in neurotrophic activity.

Visochek et al. 2005The Journal of neuroscience : the official journal of the Society for Neurosciencecited by 70

PMID 16093393PMC6725295DOI 10.1523/jneurosci.0333-05.2005PUB-16093393

Free to read · publisher termsCC BY-NC3 results where Davunetide was given

Read at source See results (3)

In vitro (cells) · rat · 2012

7 results

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Oz et al. 2012PloS onecited by 70

PMID 23272107PMC3522725DOI 10.1371/journal.pone.0051458PUB-23272107

CC BY7 results where Davunetide was given

Download PDF See results (7)

More studies

82 studies in all, 7 on this page

PubMed tag: Meta-Analysis · 2014

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

Sommer et al. 2014Schizophrenia bulletincited by 248

PMID 24106335PMC3885306DOI 10.1093/schbul/sbt139PUB-24106335

Rights unknown

Source link

PubMed tag: Meta-Analysis, review-article · 2019

An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.

Çakici et al. 2019Psychological medicinecited by 164

PMID 31439071PMC6763537DOI 10.1017/s0033291719001995PUB-31439071

CC BY

Download PDF

PubMed tag: none · 2018

Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases.

Chen et al. 2018Molecular neurodegenerationcited by 111

PMID 30089514PMC6083608DOI 10.1186/s13024-018-0270-8PUB-30089514

CC BY

Download PDF

PubMed tag: Review, Evaluation Study · 2005

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Gozes et al. 2005CNS drug reviewscited by 109

PMID 16614735PMC6741706DOI 10.1111/j.1527-3458.2005.tb00053.xPUB-16614735

Rights unknown

Source link

PubMed tag: Meta-Analysis, Systematic Review · 2019

Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials.

Cho et al. 2019The Australian and New Zealand journal of psychiatrycited by 100

PMID 30864461DOI 10.1177/0004867419835028PUB-30864461

Full text at the publisher

Publisher page

PubMed tag: Multicenter Study · 2016

Progression of brain atrophy in PSP and CBS over 6 months and 1 year.

Dutt et al. 2016Neurologycited by 88

PMID 27742814PMC5109951DOI 10.1212/wnl.0000000000003305PUB-27742814

Rights unknown

Source link

PubMed tag: Review · 2009

Addressing Alzheimer's disease tangles: from NAP to AL-108.

Gozes et al. 2009Current Alzheimer researchcited by 73

PMID 19874271DOI 10.2174/156720509789207895PUB-19874271

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Davunetide studies: 90 papers with results

Page 1 of 2

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Boxer AL · The Lancet. Neurology · 2014
Randomized controlled trial · 7 results
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
Jarskog LF · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
Randomized controlled trial · 4 results
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
Morimoto BH · Dementia and geriatric cognitive disorders · 2013
Randomized controlled trial · 3 results
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC · Schizophrenia research · 2012
Randomized controlled trial · 9 results
Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.
Gozes I · Translational psychiatry · 2023
Non-randomized trial · 6 results
Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.
Gozes I · Translational psychiatry · 2024
Non-randomized trial · 2 results
Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).
Gozes I · Translational psychiatry · 2025
Non-randomized trial · 4 results
Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.
Shapira G · Molecular psychiatry · 2026
Observational study · 5 results
Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.
Bassan M · Journal of neurochemistry · 1999
Animal study (in vivo) · mouse · 7 results
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I · The Journal of pharmacology and experimental therapeutics · 2007
Animal study (in vivo) · mouse · 2 results
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y · The Journal of pharmacology and experimental therapeutics · 2008
Animal study (in vivo) · mouse · 4 results
Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z · Biomaterials · 2013
Animal study (in vivo) · mouse · 2 results
Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.
Spong CY · The Journal of pharmacology and experimental therapeutics · 2001
Animal study (in vivo) · mouse · 5 results
B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide.
Liu Z · Bioconjugate chemistry · 2013
Animal study (in vivo) · mouse · 3 results
Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.
Hacohen-Kleiman G · The Journal of clinical investigation · 2018
Animal study (in vivo) · mouse · 8 results
NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.
Jouroukhin Y · Neurobiology of disease · 2013
Animal study (in vivo) · mouse · 9 results
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N · Neurobiology of disease · 2009
Animal study (in vivo) · mouse · 3 results
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.
Merenlender-Wagner A · Autophagy · 2014
Animal study (in vivo) · mouse · 5 results
Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.
Alcalay RN · Neuroscience letters · 2004
Animal study (in vivo) · mouse · 5 results
NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
Quraishe S · Molecular psychiatry · 2013
Animal study (in vivo) · drosophila · 2 results
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Fleming SM · Molecular and cellular neurosciences · 2011
Animal study (in vivo) · mouse · 2 results
Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies.
Karmon G · Biological psychiatry · 2022
Animal study (in vivo) · mouse · 4 results
SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.
Ivashko-Pachima Y · Molecular psychiatry · 2022
Animal study (in vivo) · mouse · 4 results
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A · Peptides · 2010
Animal study (in vivo) · mouse · 2 results
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.
Idan-Feldman A · Neurobiology of disease · 2011
Animal study (in vivo) · rat · 5 results
The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
Gozes I · Current Alzheimer research · 2005
Animal study (in vivo) · mouse · 3 results
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.
Magen I · Pharmacology research & perspectives · 2014
Animal study (in vivo) · mouse · 7 results
Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death.
Scuderi S · Journal of molecular neuroscience : MN · 2014
Animal study (in vivo) · rat · 5 results
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Vaisburd S · Scientific reports · 2015
Animal study (in vivo) · mouse · 4 results
Strategies to defeat ketamine-induced neonatal brain injury.
Turner CP · Neuroscience · 2012
Animal study (in vivo) · rat · 1 result
Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain.
Sharma NK · Peptides · 2011
Animal study (in vivo) · rat · 7 results
NAP prevents acute cerebral oxidative stress and protects against long-term brain injury and cognitive impairment in a model of neonatal hypoxia-ischemia.
Greggio S · Neurobiology of disease · 2011
Animal study (in vivo) · rat · 6 results
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.
Zemlyak I · Journal of neurochemistry · 2009
Animal study (in vivo) · rat · 3 results
Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss.
Zhou FC · Alcoholism, clinical and experimental research · 2008
Animal study (in vivo) · mouse · 3 results
ADNP is essential for sex-dependent hippocampal neurogenesis, through male unfolded protein response and female mitochondrial gene regulation.
Shapira G · Molecular psychiatry · 2025
Animal study (in vivo) · mouse · 3 results
D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I · Journal of molecular neuroscience : MN · 2016
Animal study (in vivo) · rat · 3 results
NAP prevents hippocampal oxidative damage in neonatal rats subjected to hypoxia-induced seizures.
Greggio S · Neurobiology of disease · 2009
Animal study (in vivo) · rat · 3 results
Integrated ribosome and proteome analyses reveal insights into sevoflurane-induced long-term social behavior and cognitive dysfunctions through ADNP inhibition in neonatal mice.
Liang LR · Zoological research · 2024
Animal study (in vivo) · mouse · 4 results
Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats.
Zhang J · Physiology & behavior · 2017
Animal study (in vivo) · rat · 5 results
Neurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse.
Sari Y · Journal of molecular neuroscience : MN · 2013
Animal study (in vivo) · mouse · 3 results
Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.
Sethy NK · Journal of molecular neuroscience : MN · 2014
Animal study (in vivo) · rat · 8 results
Drosophila wing is a high-throughput and versatile screening tool for Tau-mediated disease mechanisms and drug discovery.
Ramirez-Moreno M · Disease models & mechanisms · 2026
Animal study (in vivo) · drosophila · 1 result
NAP peptide modulated proteome profiling of rat brain cortex under hypobaric hypoxia.
Sharma NK · Respiratory physiology & neurobiology · 2026
Animal study (in vivo) · rat · 6 results
Activity-dependent neuroprotective protein (ADNP) derived peptide NAP prevents musculoskeletal abnormalities in ovariectomized mice.
Guz LS · Frontiers in neuroscience · 2026
Animal study (in vivo) · female icr mice · 2 results
Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.
Schaak A · Epilepsy research · 2026
Animal study (in vivo) · caenorhabditis elegans · 1 result
NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model.
Van Dijck A · Peptides · 2009
Animal study (in vivo) · mouse · 1 result
Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.
Wilkemeyer MF · Proceedings of the National Academy of Sciences of the United States of America · 2003
Ex vivo tissue · mouse · 2 results
Peptide-mediated protection from ethanol-induced neural tube defects.
Chen SY · Developmental neuroscience · 2005
Ex vivo tissue · mouse · 1 result
Ethanol antagonist peptides: structural specificity without stereospecificity.
Wilkemeyer MF · The Journal of pharmacology and experimental therapeutics · 2004
Ex vivo tissue · mouse · 1 result
The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
Esteves AR · Biochimica et biophysica acta · 2014
In vitro (cells) · 8 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	FDA records an ADNP syndrome orphan designation dated 2018-02-22. The record states that davunetide is not FDA approved for that indication. UNII assignment does not establish approval.	27 Oct 2026	accessdata.fda.gov (opens in a new tab)
EU	EMA	EMA records orphan designation EU/3/24/3007 for ADNP syndrome, dated 2024-12-13. This is not marketing authorisation. The sponsor withdrew the earlier PSP orphan designation in April 2013. These records do not establish current national approvals.	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Status unknown The 2026 list does not name davunetide.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

8 safety results for Davunetide.

Human evidence· 7

In patients with PSP, davunetide and placebo each had 54 serious adverse events.
Randomized controlled trialn = 313
Serious adverse events
54 events
davunetide
Serious adverse events
54 events
placebo
In patients with PSP, 11 deaths occurred with davunetide versus ten with placebo.
Randomized controlled trialn = 313
Deaths
11 deaths
davunetide
Deaths
10 deaths
placebo
In patients with PSP, epistaxis occurred in 18 (12%) with davunetide versus 13 (8%) with placebo.
Randomized controlled trialn = 312
Epistaxis
18 participants
davunetide
Epistaxis
12%
davunetide
Epistaxis
13 participants
placebo
1 more measurement in the study.
In patients with PSP, rhinorrhoea occurred in 15 (10%) with davunetide versus eight (5%) with placebo.
Randomized controlled trialn = 312
Rhinorrhoea
15 participants
davunetide
Rhinorrhoea
10%
davunetide
Rhinorrhoea
8 participants
placebo
1 more measurement in the study.
In patients with PSP, nasal discomfort occurred in 15 (10%) with davunetide versus one (<1%) with placebo.
Randomized controlled trialn = 312
Nasal discomfort
15 participants
davunetide
Nasal discomfort
10%
davunetide
Nasal discomfort
1 participants
placebo
1 more measurement in the study.
In amnestic mild cognitive impairment, AL-108 was generally safe and well tolerated.
Randomized controlled trialn = 144
In schizophrenia, the davunetide trial reported no significant side effects or adverse events.
Randomized controlled trialn = 63

Animal evidence· 1

In transgenic mice, no adverse effects were found after 6 months of NAP exposure.
Animal study (in vivo)Mouse

Doses studied · 30

The doses that these studies used. They are not recommendations.

30 mg twice dailyHuman
Species
human
Route
intranasal
Duration
52 weeks
Design
Randomized controlled trial · n = 313
30 mg/dayHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial · n = 15
5 and 30 mg/dayHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial · n = 11
5 mg or 30 mgHuman
Species
human
Route
intranasal
Duration
12 weeks
Design
Randomized controlled trial · n = 63
5 mgHuman
Species
human
Route
intranasal
Duration
12 weeks
Design
Randomized controlled trial
30 mgHuman
Species
human
Route
intranasal
Duration
12 weeks
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
30 mg twice daily	Human	human	intranasal	52 weeks	Randomized controlled trial · n = 313
30 mg/day	Human	human	Not reported	12 weeks	Randomized controlled trial · n = 15
5 and 30 mg/day	Human	human	Not reported	12 weeks	Randomized controlled trial · n = 11
5 mg or 30 mg	Human	human	intranasal	12 weeks	Randomized controlled trial · n = 63
5 mg	Human	human	intranasal	12 weeks	Randomized controlled trial
30 mg	Human	human	intranasal	12 weeks	Randomized controlled trial

6 of 30 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000126
Peptide version: 2
Peptide hash: f1c7b19e064dc6d5…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 287286
27 Oct 2026CreatedData version 256665

For developers

curl -s https://pepbank.io/v1/briefs/davunetide

Evidence summary for Davunetide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Cognition and memoryNervous system and cognition	Human: 14 results from 5 studies: 8 increase, 5 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 23 results from 19 studies: 11 increase, 11 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	37
NeuroprotectionNervous system and cognition	Human: 6 results from 3 studies: 3 increase, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 65 results from 27 studies: 18 increase, 40 decrease, 7 not reported. Strongest design: Animal study (in vivo)	Lab: 48 results from 18 studies: 23 increase, 13 decrease, 5 no significant change, 7 not reported. Strongest design: Ex vivo tissue	No results	119
Exercise and physical functionNervous system and cognition	Human: 6 results from 3 studies: 3 decrease, 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 9 results from 6 studies: 1 increase, 4 decrease, 4 no significant change. Strongest design: Animal study (in vivo)	No results	No results	15
Adverse eventsWhole body	Human: 6 results from 3 studies: 3 increase, 3 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	7
PharmacokineticsPharmacology	Human: 2 results from 1 study: 1 increase, 1 mixed. Strongest design: Non-randomized trial	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	Lab: 3 results from 2 studies: 3 not reported. Strongest design: In vitro (cells)	No results	6
Anxiety and moodMental health and mood	Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial	Animal: 4 results from 2 studies: 1 increase, 3 decrease. Strongest design: Animal study (in vivo)	No results	No results	5
MortalityWhole body	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 2 studies: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	3
Psychiatric symptomsMental health and mood	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1
Receptor activity and mechanismWhole body	No results	Animal: 31 results from 12 studies: 12 increase, 6 decrease, 3 no significant change, 1 mixed, 9 not reported. Strongest design: Animal study (in vivo)	Lab: 58 results from 17 studies: 31 increase, 10 decrease, 5 no significant change, 12 not reported. Strongest design: Ex vivo tissue	No results	89
Immune responseImmune and inflammation	No results	No results	Lab: 4 results from 1 study: 4 decrease. Strongest design: In vitro (cells)	No results	4
Inflammation markersImmune and inflammation	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	Lab: 3 results from 1 study: 3 decrease. Strongest design: In vitro (cells)	No results	4
Mitochondrial functionNervous system and cognition	No results	No results	Lab: 4 results from 2 studies: 1 increase, 2 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	4

Outcome group	Human	Animal	Lab	Computer model	Total
Cognition and memoryNervous system and cognition	Human: 14 results from 5 studies: 8 increase, 5 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 23 results from 19 studies: 11 increase, 11 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	37
NeuroprotectionNervous system and cognition	Human: 6 results from 3 studies: 3 increase, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 65 results from 27 studies: 18 increase, 40 decrease, 7 not reported. Strongest design: Animal study (in vivo)	Lab: 48 results from 18 studies: 23 increase, 13 decrease, 5 no significant change, 7 not reported. Strongest design: Ex vivo tissue	No results	119
Exercise and physical functionNervous system and cognition	Human: 6 results from 3 studies: 3 decrease, 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 9 results from 6 studies: 1 increase, 4 decrease, 4 no significant change. Strongest design: Animal study (in vivo)	No results	No results	15
Adverse eventsWhole body	Human: 6 results from 3 studies: 3 increase, 3 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	7
PharmacokineticsPharmacology	Human: 2 results from 1 study: 1 increase, 1 mixed. Strongest design: Non-randomized trial	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	Lab: 3 results from 2 studies: 3 not reported. Strongest design: In vitro (cells)	No results	6
Anxiety and moodMental health and mood	Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial	Animal: 4 results from 2 studies: 1 increase, 3 decrease. Strongest design: Animal study (in vivo)	No results	No results	5
MortalityWhole body	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 2 studies: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	3
Psychiatric symptomsMental health and mood	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1
Receptor activity and mechanismWhole body	No results	Animal: 31 results from 12 studies: 12 increase, 6 decrease, 3 no significant change, 1 mixed, 9 not reported. Strongest design: Animal study (in vivo)	Lab: 58 results from 17 studies: 31 increase, 10 decrease, 5 no significant change, 12 not reported. Strongest design: Ex vivo tissue	No results	89
Immune responseImmune and inflammation	No results	No results	Lab: 4 results from 1 study: 4 decrease. Strongest design: In vitro (cells)	No results	4
Inflammation markersImmune and inflammation	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	Lab: 3 results from 1 study: 3 decrease. Strongest design: In vitro (cells)	No results	4
Mitochondrial functionNervous system and cognition	No results	No results	Lab: 4 results from 2 studies: 1 increase, 2 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	4

Davunetide studies and research data

Davunetide identity

Targets

Sequence and structure

Sequence

Parent: Activity-dependent neuroprotector homeobox protein

Properties

Net charge by pH

Composition

3D structure

2D structure

Davunetide results by year and outcome

What the studies measured

Davunetide studies on memory and thinking

Davunetide studies on brain and nerves

Davunetide studies on daily life and fitness

Davunetide studies on side effects

Davunetide studies on mood, stress and behavior

Davunetide studies on blood levels and clearance

Davunetide studies on survival and serious illness

Davunetide studies on receptors and cell signals

Davunetide studies on immune system and inflammation

Davunetide studies on cells, genes and aging

Davunetide studies on growth hormone and growth

Davunetide trials

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Multicenter Study of NAP (AL-108) in Schizophrenia

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Papers

Studies with results

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.

Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.

B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide.

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.

The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.

ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.

PolyADP-ribosylation is involved in neurotrophic activity.

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

More studies

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.

Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases.

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials.

Progression of brain atrophy in PSP and CBS over 6 months and 1 year.

Addressing Alzheimer's disease tangles: from NAP to AL-108.

Newer studies

Davunetide studies: 90 papers with results

Regulatory and safety

Human evidence· 7

Animal evidence· 1

Doses studied · 30

Data and API

Peptide

Latest changes

For developers

Related peptides

Davunetide results by year and outcome

Davunetide studies on memory and thinking

Davunetide studies on brain and nerves

Davunetide studies on daily life and fitness

Davunetide studies on side effects

Davunetide studies on mood, stress and behavior

Davunetide studies on blood levels and clearance

Davunetide studies on survival and serious illness

Davunetide studies on receptors and cell signals

Davunetide studies on immune system and inflammation

Davunetide studies on cells, genes and aging